Skip to main navigation

English
Français

IR Navigation

Overview
News
Events & Presentations
- Events
- Presentations
Stock Information
Financials
Governance
Resources

Press Releases

Press Releases

Year

19 Sep 2022

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

13 Sep 2022

FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

08 Jul 2022

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

25 May 2022

GENFIT: May 25, 2022 Combined Shareholders Meeting results

11 May 2022

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

29 Apr 2022

GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

20 Apr 2022

GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents

07 Apr 2022

GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update

28 Feb 2022

GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021

24 Jan 2022

GENFIT: 2022 Financial Calendar

21 Jan 2022

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Shareholder Tools

Print Page
Email Alerts
RSS
Contact IR

Request E-mail Alerts

GENFIT Headquarters
Parc Eurasanté 885, Avenue Eugène Avinée 59120 Loos France GENFIT Corp
45 Propect St. Suite 214, Cambridge, MA02139, USA

All rights reserved.